Pharmaceutical - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

151 to 175 of 423 results

GlaxoSmithKline invests further £25 million in Scottish operation

GlaxoSmithKline invests further £25 million in Scottish operation

23-11-2013

UK pharma giant GlaxoSmithKline is to invest £25 million ($40.2 million) to expand its operations in…

EuropeFinancialGlaxoSmithKlinePharmaceuticalProduction

Pfizer and GSK link up to trial combo melanoma therapy

Pfizer and GSK link up to trial combo melanoma therapy

22-11-2013

Two of the world’s pharma giants, USA-based Pfizer and the UK’s GlaxoSmithKline have joined forces…

GlaxoSmithKlineMekinistOncologypalbociclibPfizerPharmaceuticalResearchtrametinib

GlaxoSmithKline cashes in $694 million of Aspen shares

GlaxoSmithKline cashes in $694 million of Aspen shares

21-11-2013

UK pharma giant GlaxoSmithKline said yesterday that it has agreed to the sale of 28.2 million ordinary…

Aspen PharmacareFinancialGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalRest of the World

Relvar Ellipta approved for asthma and COPD in Europe

Relvar Ellipta approved for asthma and COPD in Europe

19-11-2013

The European Commission has granted marketing authorization for Relvar Ellipta (fluticasone furoate/vilanterol…

EuropeGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

18-11-2013

Despite being hampered both by apathy and resistance in recent years, the human papillomavirus (HPV)…

CervarixGardasilGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalV503VaccinesWomen's Health

GlaxoSmithKline’s darapladib flops in Ph III CHD trial

GlaxoSmithKline’s darapladib flops in Ph III CHD trial

12-11-2013

UK pharma giant GlaxoSmithKline saw its shares dip 1.3% to £16.29 in mid-morning trading, after the…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearch

Immunocore makes progress in deal with GSK

Immunocore makes progress in deal with GSK

07-11-2013

UK-based biotech firm Immunocore has achieved its first milestone in its major research and licensing…

EuropeFinancialGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearchUK

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

ViiV Healthcare’s Tivicay approved in Canada for HIV

04-11-2013

ViiV Healthcare, the HIV/AIDS joint venture set up by UK pharma giant GlaxoSmithKline with US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

New data support GSK’s Cervarix two-dose schedule

New data support GSK’s Cervarix two-dose schedule

04-11-2013

UK pharma giant GlaxoSmithKline has revealed the results of a Phase III study of its HPV vaccine, Cervarix,…

CervarixGlaxoSmithKlineOncologyPharmaceuticalResearchVaccines

Theravance and GSK launch Breo Ellipta in USA

Theravance and GSK launch Breo Ellipta in USA

30-10-2013

GlaxoSmithKline and US partner Theravance today announced that Breo Ellipta for COPD is available to…

Breo ElliptaFinancialGlaxoSmithKlineMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and PulmonaryTheravance

GSK's third quarter results shows sales hit by China investigation

GSK's third quarter results shows sales hit by China investigation

24-10-2013

UK pharma major GlaxoSmithKline has released its third quarter results with sales hit hard by the investigation…

EuropeFinancialGlaxoSmithKlinePharmaceutical

Agreements for influenza vaccine approved in New Zealand

15-10-2013

New Zealand’s PHARMAC has reached agreements with subsidiaries of GlaxoSmithKline and Abbott Laboratories…

Abbott LaboratoriesFluarixGlaxoSmithKlineHealthcareInfluvacNew ZealandPharmaceuticalPricingVaccines

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay

11-10-2013

The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Global asthma treatment market to reach $21.6 billion by 2019

09-10-2013

The global asthma treatment market is estimated to reach a value of $21.6 billion by 2019, due not only…

GlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

New data support GSK plan to file for approval of malaria vaccine in 2014

New data support GSK plan to file for approval of malaria vaccine in 2014

08-10-2013

Results from a large-scale Phase III trial, presented today at the Multilateral Initiative on Malaria…

GlaxoSmithKlinePharmaceuticalRegulationResearchRTS,STropical diseasesVaccines

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

GSK and Genmab file for Arzerra variation in Europe

04-10-2013

GlaxoSmithKline ) and partner Genmab have submitted a variation to the Marketing Authorization to the…

ArzerraBiotechnologyEuropeGenmabGlaxoSmithKlineOncologyPharmaceuticalRegulation

GSK stock will remain strong despite slowing emerging markets, say analysts

GSK stock will remain strong despite slowing emerging markets, say analysts

04-10-2013

Following concerns from Eli Lilly about the slowdown of emerging markets and devaluation of the Japanese…

EuropeFinancialGlaxoSmithKlineGSKPharmaceutical

GlaxoSmithKline agrees £700 million deal with Aspen

GlaxoSmithKline agrees £700 million deal with Aspen

30-09-2013

GlaxoSmithKline says it has now reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine,…

ArixtraAspen PharmacareCardio-vascularFraxiparineGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalRest of the World

151 to 175 of 423 results

Back to top